Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response.

Cerebrospinal fluid (CSF) samples were examined from 7 patients infected with human immunodeficiency virus type 1 (HIV-1) who had progressive multifocal leukoencephalopathy (PML). Samples were obtained both before and after 35-365 days of highly active antiretroviral therapy (HAART). By polymerase chain reaction, JC virus (JCV) DNA was found in 6 of 7 patients at baseline but in only 1 patient after HAART. In contrast, in 25 historical control patients from whom sequential CSF specimens were obtained, no reversion from detectable to undetectable JCV DNA was observed. By use of enzyme-linked immunosorbent assay, intrathecal production of antibody to JCV-VP1 was shown in only 1 of 4 HAART recipients at baseline but in 5 of 5 patients after treatment. The neuroradiological picture improved or had stabilized in all patients after 12 months of HAART, and all were alive after a median of 646 days (range, 505-775 days). Prolonged survival after HAART for PML is associated with JCV clearance from CSF. JCV-specific humoral intrathecal immunity may play a role in this response.

[1]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[2]  W. Andler,et al.  Liquorice, Growth Retardation and Addison’s Disease , 1999, Hormone Research in Paediatrics.

[3]  C. Yiannoutsos,et al.  Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy‐proven progressive multifocal leukoencephalopathy , 1999, Annals of neurology.

[4]  A. Antinori,et al.  Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  E. Bouza,et al.  Dual Qualitative-Quantitative Nested PCR for Detection of JC Virus in Cerebrospinal Fluid: High Potential for Evaluation and Monitoring of Progressive Multifocal Leukoencephalopathy in AIDS Patients Receiving Highly Active Antiretroviral Therapy , 1999, Journal of Clinical Microbiology.

[6]  D M Simpson,et al.  HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy , 1999, Neurology.

[7]  N. Letvin,et al.  JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy , 1999, Neurology.

[8]  R. Brack-Werner.  Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. , 1999, AIDS.

[9]  E. Bouza,et al.  Treatment of AIDS‐associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy , 1998, AIDS.

[10]  C. Goujard,et al.  Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. , 1998, The Journal of infectious diseases.

[11]  P. Cinque,et al.  Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy. , 1998, The New England journal of medicine.

[12]  R. Levy,et al.  Predictive factors for prolonged survival in acquired immunodeficiency syndrome—associated progressive multifocal leukoencephalopathy , 1998, Annals of neurology.

[13]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[14]  H. Stellbrink,et al.  Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV‐associated progressive multifocal leukoencephalopathy , 1998, AIDS.

[15]  U. Dafni,et al.  Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. , 1998, The New England journal of medicine.

[16]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[17]  N. Letvin,et al.  Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease , 1998, The Lancet.

[18]  Henry J. Kaiser,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[19]  D. Lanska,et al.  Progressive multifocal leukoencephalopathy in patients with HIV infection. , 1998, Journal of neurovirology.

[20]  W. Kucharczyk,et al.  Regression of progressive multifocal encephalopathy with highly active antiretroviral therapy. , 1997, AIDS.

[21]  H. Kretzschmar,et al.  Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. , 1997, The Journal of infectious diseases.

[22]  Á. Iranzo,et al.  Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy , 1997, The Lancet.

[23]  J. Catalan,et al.  Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy , 1997, The Lancet.

[24]  H. Schønheyder,et al.  Reasons for increase in pneumococcal bacteraemia , 1997, The Lancet.

[25]  T. Flanigan,et al.  2·5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy , 1997, The Lancet.

[26]  A. Nath,et al.  Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection. , 1997, The New England journal of medicine.

[27]  A. Lazzarin,et al.  Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. , 1997, AIDS.

[28]  E. Major,et al.  Progressive multifocal leukoencephalopathy: molecular biology, pathogenesis and clinical impact. , 1997, Intervirology.

[29]  A. Lazzarin,et al.  Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients , 1996, AIDS.

[30]  E. Major,et al.  Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain , 1992, Clinical Microbiology Reviews.

[31]  K. Khalili,et al.  Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Bonnin,et al.  Progressive multifocal leukoencephalopathy: three patients diagnosed by brain biopsy, with prolonged survival in two. , 1986, Neurosurgery.

[33]  E. Richardson.  Progressive multifocal leukoencephalopathy. , 1961, The New England journal of medicine.

[34]  Thomas K. Hunt,et al.  ON THE TREATMENT OF , 1846 .